JeanMarie Guenot is currently the President and Chief Executive Officer (CEO) of Amphivena Therapeutics; this is a company that develops immune therapies for the treatment of cancer patients, located in San Francisco. Jeanmarie Guenot went to Wharton School at the University Of Pennsylvania, where she studied a Master’s In Business Administration (MBA), between the year 1999 and the year 2001. JeanMarie Guenot before, back in 1987 to the year 1993 she attained a doctorate (Ph.D.) from the University of California, based in San Francisco. JeanMarie has an over two decades experience in the pharmaceutical and biotechnology industry on guenotllc.com.
Before her current role at Amphivena Therapeutics, Jeanmarie Guenot offers consultation services, in the fields of project management, economic planning, and finance among others in biotechnology and pharmaceutical industries. Guenot has worked with many public and private organizations, in the position of project and alliance management, business development, pharmaceutical officer and commercial development. Guenot’s scientific career began at Hoffman-La Roche, where she worked as Principal Scientist, Team Leader and Preclinical R&D, for six years from 1993 to the year 1999. After that, Guenot joined Atlas Venture and worked and an Associate and Life scientist for three years. In the year 2003 to 2008, Guenot worked as the Vice President, Corporate and Business developer at PDL Biopharma. Later in 2009, JeanMarie Guenot founded an organization by the name SKS Ocular, LLC and she worked there as the first employee.
Being the founder of SKS Ocular, LLC company, JeanMarie focused on medication of dry AMD, and she sustained the release of Ocular drug delivery technologies, therapeutics for glaucoma, Ocular inflammation and macular degeneration. In her career, JeanMarie has been an expert in building and renovating pharmaceutical companies, Guenot has experience in management and leadership of prominent companies. She has been successful in her professional skills, integrity, and hard work throughout her career.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance